Agilent Technologies, Inc. Q3 FY2025 earnings call

• Agilent delivered $1.74 billion in revenue in Q3, exceeding guidance, with 5th consecutive quarter of sequential core revenue acceleration. • Raised fiscal 2025 full-year revenue guidance to $6.91-$6.93 billion, core growth 4.5% midpoint, a $150 million increase from prior range. • Momentum broad-based, led by pharma (9% growth) and chemicals/advanced materials (10% growth). • Ignite enterprise operating model driving pricing, cost reduction (reduced management layers by >15%), and supply chain optimization. • Innovation with new product launches like Infinity Tree LC platform, Pro IQ LCMS system, and DACO OMDAS family.

The life science and diagnostics markets group (LDG) grew 7% core growth, led by low double-digit performance for LC and LC MS instruments, with NASD growing in the high twenties and BioVectra delivering as expected. The applied markets group (AMG) saw 5% growth, with market-leading platforms GC, GCMS, and spectroscopy driving strong growth in Q3, led by Asia ex China and EMEA. The Agilent CrossLab Group delivered 5% growth, with mid-single-digit consumables growth supported by e-commerce and digital, and services business growing mid-single digits.

• Raised fiscal 2025 full-year revenue to $6.91-$6.93 billion, core growth 4.5% midpoint. • Q4 revenue expected $1.82-$1.84 billion, core growth 4.8-6%, non-GAAP EPS $1.57-$1.60. • Tariff impact expected to fully mitigate in FY 2026, with headwind peaking in Q4 2026.

• Tariff impacts on shipments and inventory leading to higher than expected expenses. • Uncertainties in macroeconomic conditions and federal funding in US academia and government affecting some end markets.

Q: Dan Brennan asked about margins and variables affecting them.

A: Padraig and Rodney discussed tariffs, commercial investments, and variable pay, noting tariffs, incremental commercial investment, and higher variable pay as factors.

Q: Tycho Peterson inquired about pharma sign-off dependency and PFAS performance.

A: Padraig and Simon May discussed pharma sign-off dependency improving globally and PFAS having low double-digit growth globally with Americas down due to US EPA changes.

Q: Rachel Vatnsdal asked about 2026 expectations and budget flush assumptions.

A: Padraig and Rodney talked about momentum carrying into 2026 and budgets normalizing with larger quotes seen.

Q: Michael Ryskin asked about chemicals/advanced materials growth and tariff margin impact.

A: Padraig and Rodney discussed chemicals/advanced materials growth drivers and tariff impact on margins.

Q: Patrick Donnelly asked about pricing and margin expectations.

A: Rodney mentioned about 100 bps improvement in pricing.

Q: Jack Meehan asked about China diagnostics market exposure and trade tariff customer behavior.

A: Padraig and Simon May discussed low exposure to China diagnostics and no further consumable pull forwards.

Q: Vijay Kumar asked about top-line growth and M&A readiness.

A: Padraig talked about M&A being a more meaningful part of capital deployment with disciplined approach.

Q: Doug Schenkel asked about capital deployment and organizational readiness.

A: Padraig discussed M&A readiness and disciplined approach to capital deployment.

Q: Puneet Souda asked about momentum acceleration and China stimulus.

A: Padraig and Mike Zhang talked about Q3 momentum and potential China stimulus benefits.

Q: Dan Leonard asked about pricing clarification and chemical replacement opportunity.

A: Rodney clarified pricing and Mike Zhang discussed chemical replacement opportunity with new product launches.